Impact of Fc {gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan, J Clin Oncol, vol.27, pp.1122-1129, 2009. ,
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer, Cancer Discov, vol.4, pp.606-619, 2014. ,
Physiological and pathological consequences of cellular senescence, Cell Mol Life Sci, vol.71, pp.4373-4386, 2014. ,
Acquired resistance to TKIs in solid tumours: learning from lung cancer, Nat Rev Clin Oncol, vol.11, pp.473-481, 2014. ,
Senescence response to oxidative & genotoxic stress: a link between aging and disease, Free Radic Biol Med, vol.53, p.9, 2012. ,
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18, Br J Pharmacol, vol.173, pp.1407-1424, 2016. ,
Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000. ,
Whacking a mole-cule: clinical activity and mechanisms of resistance to third generation EGFR inhibitors in EGFR mutated lung cancers with EGFR-T790M, Transl Lung Cancer Res, vol.4, pp.809-815, 2015. ,
The role of P53 tumor-suppressor in cellular replicative senescence, FASEB J, vol.9, p.1464, 1995. ,
Acquired resistance to the mutant-selective EGFR inhibitor AZD9291 is associated with increased dependence on ras signaling in preclinical models, Can Res, vol.75, pp.2489-2500, 2015. ,
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo-and heterodimers, Int J Cancer, vol.139, pp.2095-2105, 2016. ,
Living on a break: cellular senescence as a DNAdamage response, Nat Rev Cancer, vol.8, pp.512-522, 2008. ,
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3, Hum Vaccin Immunother, vol.3, pp.1-17, 2015. ,
Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas, PLoS Med, vol.4, p.294, 2007. ,
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat Med, vol.22, pp.262-269, 2016. ,
dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells, J Exp Med, vol.210, pp.2057-2069, 2013. ,
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations, Cancer Discov, vol.4, pp.1036-1045, 2014. ,
AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer, N Engl J Med, vol.372, pp.1689-1699, 2015. ,
Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer, Drugs, vol.74, pp.207-221, 2014. ,
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.352, pp.786-792, 2005. ,
,
HER3, serious partner in crime therapeutic approaches and potential biomarkers for effect of HER3-targeting, 2014. ,
, Pharmacol Ther, vol.143, pp.1-11
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer, Curr Opin Oncol, vol.27, pp.94-101, 2015. ,
Epidermal EGFR controls cutaneous host defense and prevents inflammation, Sci Transl Med, vol.5, pp.199-111, 2013. ,
Non-cell-autonomous tumor suppression by p53, Cell, vol.153, pp.449-460, 2013. ,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.350, pp.2129-2139, 2004. ,
Lipoplex mediated silencing of membrane regulators (CD46, CD55 and CD59) enhances complement-dependent anti-tumor activity of trastuzumab and pertuzumab, Mol Oncol, vol.7, pp.580-594, 2013. ,
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer, The Authors EMBO Molecular Medicine, vol.8, issue.2, 2015. ,
Mutational and network level mechanisms underlying resistance to anti-cancer kinase inhibitors, Semin Cell Dev Biol, vol.50, pp.164-176, 2015. ,
Recognition of tumors by the innate immune system and natural killer cells, Adv Immunol, vol.122, pp.91-128, 2014. ,
Gefitinib or carboplatinpaclitaxel in pulmonary adenocarcinoma, N Engl J Med, vol.361, pp.947-957, 2009. ,
Osimertinib or platinumpemetrexed in EGFR T790M-positive lung cancer, N Engl J Med, vol.376, pp.629-640, 2017. ,
Cellular senescence: from physiology to pathology, Nat Rev Mol Cell Biol, vol.15, pp.482-496, 2014. ,
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer, J Clin Oncol, vol.26, pp.1789-1796, 2008. ,
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer, Clin Cancer Res, vol.17, pp.5530-5537, 2011. ,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, vol.304, pp.1497-1500, 2004. ,
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc Natl Acad Sci, vol.101, pp.13306-13311, 2004. ,
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain, PLoS Med, vol.2, p.73, 2005. ,
Acquired resistance of EGFR-mutant lung adenocarcinomas to afatinib plus cetuximab is associated with activation of mTORC1, Cell Rep, vol.7, pp.999-1008, 2014. ,
EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients, Ann Oncol, vol.26, pp.2073-2078, 2015. ,
Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells, Nat Commun, vol.7, p.10690, 2016. ,
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer, J Clin Investig, vol.119, pp.3000-3010, 2009. ,
Screening for epidermal growth factor receptor mutations in lung cancer, N Engl J Med, vol.361, pp.958-967, 2009. ,
Immunosurveillance of senescent cells: the bright side of the senescence program, Biogerontology, vol.14, pp.617-628, 2013. ,
Cellular senescence and its effector programs, Genes Dev, vol.28, pp.99-114, 2014. ,
Evaluation of digital PCR for absolute RNA quantification, PLoS One, vol.8, p.75296, 2013. ,
Rociletinib in EGFR-mutated non-smallcell lung cancer, N Engl J Med, vol.373, pp.578-579, 2015. ,
Cancer final act of senescence, Nature, vol.479, pp.481-482, 2011. ,
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M, Nat Med, vol.21, pp.560-562, 2015. ,
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas, Nature, vol.445, pp.656-660, 2007. ,
Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component, J Clin Oncol, vol.35, pp.1288-1296, 2017. ,
, Phase I trial of the irreversible EGFR and HER2, 2010.
, kinase inhibitor BIBW 2992 in patients with advanced solid tumors, J Clin Oncol, vol.28, pp.3965-3972
FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab, J Clin Oncol, vol.25, pp.3712-3718, 2007. ,
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M, Nature, vol.462, pp.1070-1074, 2009. ,
, License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited
, EMBO Molecular Medicine, vol.10, issue.2, 2017.